Global Pharmaceuticals Industry

News provided by

Mar 05, 2012, 05:16 ET

NEW YORK, March 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pharmaceuticals Industry

http://www.reportlinker.com/p0788343/Global-Pharmaceuticals-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_D

The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Punctuated with 46 statistically rich tables, the report provides an overview of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as patent expiry of blockbuster global drugs, increasing biogenerics, among others. The report offers an in-depth analysis of the pharmaceutical industry, highlights latest trends and demand drivers, the recent FDA approvals, the current and the impending patent expiries, in addition to providing statistical insights. The report also recapitulates recent noteworthy mergers, acquisitions, and other strategic developments. The report briefly discusses the pharmaceutical market outlook across various markets worldwide. Regional markets extensively discussed in the report include the United States, Canada, Japan, China, Germany, South Korea and India, among several others. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 2,589 companies worldwide.

1. GLOBAL OUTLOOK 1Global Pharmaceutical Market - Hit, but Not Down 1Cost Containment and Patent Expirations Affect Market Growth 1Industry Seeks Measures to Sustain Future Growth 2Outlook Remains Positive, Yet Tempered 2Table 1: World Recent Past, Current & Future Analysis forPrescription Pharmaceutical Market by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific, Latin American and Restof World Markets Independently Analyzed with Annual SalesFigures in US$ Billion for Years 2010 through 2015 3

Table 2: World 5-Year Perspective for Prescription

Pharmaceuticals by Geographic Region - Percentage Breakdown

of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific,

Latin America and Rest of World Markets for Years 2011 and

2015 4

Oncologics - The Largest Drug Class in the Global Prescription

Pharmaceutical Market 5

Table 3: World Recent Past, Current & Future Analysis for

Prescription Pharmaceuticals by Therapeutic Class -

Angiotensin II Antagonists, Antidepressants, Antidiabetics,

Anti-epileptics, Antipsychotics, Anti-ulcerants, Autoimmune

agents, Lipid Regulators, Oncologics, Respiratory Agents and

Others Markets Independently Analyzed with Annual Sales

Figures in US$ Billion for Years 2010 through 2015 6

Table 4: World 5-Year Perspective for PrescriptionPharmaceuticals by Therapeutic Class - Percentage Breakdownof Dollar Sales for Angiotensin II Antagonists,Antidepressants, Antidiabetics, Anti-epileptics,Antipsychotics, Anti-ulcerants, Autoimmune agents, LipidRegulators, Oncologics, Respiratory Agents and Others Marketsfor Years 2011 and 2015 7Major Challenges Faced by the Global Pharma Industry 8Key Opportunities 8Generic Drug Sales Soar 8Authorized Generics - A Major Concern for Generic Makers 8Increasing Focus on Emerging Markets 8

2. MARKET TRENDS 10

Pharmaceutical Industry Fares Relatively Well During Recession 10

Fallout of Recession on the Pharmaceutical Market - Largely an

Indirect Effect 10

Patent Cliff Hurts Pharma Industry, Brings Smiles on the Faces

of Payers 10

The Patent Cliff: Select Major Drugs Going Off-Patent during

2011-2015 11

Cost Containment Comes as a Double Blow to the Global Pharma 12

Global Pharma Alters Strategy - Lays More Emphasis on

Specialty Areas 12

Innovation Continues in R&D Methods 12

Aging Population - A Major Driver of Pharmaceutical Growth 12

Market Booming for Old Age Related Medications 13

Rising Prominence of Biopharmaceuticals 13

Select FDA-Approved Biopharmaceuticals in 2010 14

Biotech Future Appears Bright 14

Focus on OTC Drugs Rising 14

Manufacturers Dump Conventional Approaches to Play Safe 15

High Fragmentation Typifies the Global Generic Drug Sector 15

Table 5: Leading Companies in the Global Generic Drugs Market

(2010): Percentage Breakdown by Value Sales for Teva

Pharmaceutical Industries, Sandoz, Mylan Laboratories,

Watson, Ratiopharm, and Others 15

Significant Potential for Consolidation Activity Exists in the

Generic Drug Sector 16

Global Majors Chart Acquisition Route in Developing Economies 16

Expanding Opportunities through In-Licensing 16

Differentiation & Innovation - Key in the Competitive Market 17

Virtual Techniques March Ahead 17

Big Pharma Companies Cashing in on the Biosimilars Drive 17

Biosimilar Uptake in Developed Markets Thus Far 18

Technologies to Gear up Research 18

Cloud Computing to Better Pharmaceutical Sector 18

Biotherapies to Drive Growth in Cancer Therapy Market 19

Oncology Drugs - the Leader in the Global Pharma Pipeline 19

Vaccine Demand on the Rise 19

China and India Emerge as Major Contract Manufacturing Hubs 20

Global Analgesics Market to Soar 20

Nano-Enabled Drug Discovery Geared to Lead 20

Proteomics - The Current Spotlight 21

Neurodegeneration Treatments Identified in Research 21

3. MAJOR ISSUES/CHALLENGES 22Horde of Issues Bog Down Global Pharma Industry 22Challenges Abound in OTC Business for the Pharma Industry 22High Cost of Pharmaceuticals Challenge Large Scale Adoption 22Regulatory Pressures - A Bone of Contention 22Big Pharma R&D Pipelines are Drying Up 23Legal and Infrastructure Hurdles in Emerging Markets - AConcern for Global Pharma Industry 23

4. COMPETITIVE LANDSCAPE 24

Consolidation Activity Remains Rife 24

Table 6: Global Pharmaceutical M&A Activity in Transaction

Volume by Country/Region: 2010 24

Table 7: Global Pharmaceutical M&A Activity in TransactionValue by Country: 2010 24

Table 8: Global M&A Activity by Therapeutic Area (2010):

Percentage Breakdown of Number of Deals for Oncology,

Cardiovascular, Central Nervous System, Dermatology,

Gastro-Intestinal and Others 25

Table 9: Select Acquisitions in the Pharmaceutical IndustryWorldwide: 2011 25Table 10: Select Acquisitions in the Pharmaceutical IndustryWorldwide: 2010 26Leading Pharma Companies 27Table 11: Leading Pharmaceutical Manufacturers Worldwide byRevenues: 2009 & 2010 27Major Products 27Table 12: Leading Pharmaceutical Products Worldwide by Sales:2009 & 2010 27

5. MERGERS AND ACQUISITIONS ACTIVITY IN THE PHARMA INDUSTRY 28

6. STRATEGIC CORPORATE DEVELOPMENTS 63

7. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST 79

8. PRODUCT APPROVALS/LAUNCHES 82A REGIONAL MARKET PERSPECTIVE 92

1. THE UNITED STATES 92

US Market Outlook 92

Recession Impacts US Pharma Industry 92

Generic Drugs Dominate in Prescriptions, Share Still Languish

in Value 92

Table 13: Leading Companies in the US Generic Drugs Market

(2010): Percentage Breakdown by Value Sales for Teva

Pharmaceutical Industries, Mylan Laboratories, Watson,

Sandoz, Mallinckrodt and Others 93

Biopharmaceuticals - The New Rage for US Pharma 93

Biopharmaceutical R&D Expenditure Stays Positive; Loses Pace 93

Table 14: R&D Expenditure In the US Pharmaceutical Industry:

2006-2010 94

FDA Approvals Rise after Prolonged Stagnancy 94

Select Major New Drugs Approved by FDA in 2011 94

Select Major New Drugs Approved by FDA in 2010 95

What Lies Ahead of the Pharma Industry in the Wake of

Increasing Stress? 96

Drug Shortages Pose Enormous Challenges 96

US Biopharmaceutical Industry - R&D and Trade 97

Table 15: US Exports of Biopharmaceuticals: 2005-2010 97

Medicare - The Leading Expenditure Coverage Source in the US 98

Table 16: Prescription Drug Expenditure in the US by Payer

(2005 & 2010): Percentage Breakdown of Expenditure for

Medicare, Medicaid and Others 98

Competitive Scenario 98

Table 17: Leading Pharmaceutical Companies in the US by

Prescription Drug Revenue: 2009 & 2010 99

Table 18: Leading Pharmaceutical Companies in the US by TotalPrescriptions: 2009 & 2010 99Leading Products 100Table 19: Leading Prescription Drugs in the US by ValueSales: 2009 & 2010 100

Table 20: Leading Prescription Drugs in the US by Dispensed

Prescriptions: 2009 & 2010 101

Table 21: Leading Generic Drugs in the US by TotalPrescriptions: 2010 102

Table 22: Leading Brands in the US Eye/Lens Care Solutions

Market by Value Sales at Drug Stores: 2009 102

Table 23: Leading Brands in the US Eye/Lens Care SolutionsMarket by Unit Sales at Drug Stores: 2009 103Pharmaceutical Distribution 103Table 24: US Prescription Pharmaceutical Market byDistribution Channel (2009 & 2010): Percentage Breakdown ofRevenues for Chain Stores, Mail Service, Independent Stores,Clinics, Private Hospitals and Others 103

Table 25: US Prescription Pharmaceutical Market by

Distribution Channel (2009 & 2010): Percentage Breakdown of

Total Prescriptions for Chain Stores, Independent Stores,

Food Stores and Others 104

2. CANADA 105Canadian Pharmaceutical Market to Grow Steadily 105Canadian Pharmaceutical Industry - An Overview 105Retail Prescriptions Rise in Canada 105Generic Drugs Continue to Capture Higher Market Share 106Pharmaceutical Spending Reaches Calamitous Levels in Canada 106Table 26: Share of Expenditure on Drugs in the Total CanadianHealthcare Expenditure (1975-2010) 107Is Excessive Supply a Cause of Higher Drug Spending in Canada? 107Regulations on Generic Drugs in Canada 107Key Statistics 108Table 27: Leading Therapeutic Classes in the CanadianPharmaceutical Market by Total Prescriptions: 2008-2010 108

Table 28: Leading Drugs in the Canadian Pharmaceutical Market

by Total Prescriptions: 2008 & 2009 109

Table 29: Leading Companies in the Canadian PharmaceuticalMarket by Revenue: 2008 & 2009 110

3. JAPAN 111

Market Overview 111

Horde of Factors Result in Japanese Pharma Market Slowdown 111

Industry Endeavors to Catch up with Generic Fervor 111

New Initiatives in 2010 Drug Price Revision 112

Table 30: Japanese Generic Drug Market by Revenues: 2007-2011 112

Companies Struggle for Profitability amid Patent Expirations 112

Sluggish Domestic Demand Forces Japanese Companies to Seek

Overseas Opportunities 113

Japanese Government Presses for Increased Use of Generic Drugs 113

Competition 113

The Mergers and Acquisitions in the Industry 113

Major Acquisitions of Japanese Pharmaceutical Companies:

2007-2011 114

4. EUROPE 115European Countries Gear Up for Cost Containment Measures 115Table 31: European Recent Past, Current & Future Analysis forPrescription Pharmaceuticals by Geographic Region - France,Germany, Italy, UK, Spain and Rest of Europe MarketsIndependently Analyzed with Annual Sales Figures in US$Billion for Years 2010 through 2015 116

Table 32: European 5-Year Perspective for Prescription

Pharmaceuticals by Geographic Region - Percentage Breakdown

of Dollar Sales for France, Germany, Italy, UK, Spain and

Rest of Europe Markets for Years 2011 and 2015 117

4a. FRANCE 118The French Pharmaceutical Market - An Overview 118Measures in Place to Promote Cost Containment 118Austerity Measures to Trim Pharmaceutical Market Size 118

4b. GERMANY 119

German Market Continues to Rise 119

Germany Mulls Over Various Cost Cutting Measures 119

Table 33: German Pharmaceutical Production by Value:

2001-2010 119

4c. ITALY 120Italian Pharmaceuticals Sector Dogged by Various Factors 120Government Support Key for Growth of Innovation 120Mid-Sized Firms: to Rise in Prominence 120

4d. THE UNITED KINGDOM 121

Planned Cost Cuts to Suppress Growth 121

Is UK's Pharma R&D Strength in Danger? 121

Pfizer Continues to Rule the UK Pharmaceutical Market 122

Table 34: Percentage Share Breakdown of Sales in the UK

Pharmaceutical Market by Leading Players: 2010 122

4e. SPAIN 123Cost-Containment Measures to Drub Market Growth 123Patented Drugs Dominate the Market 123Table 35: Spanish Pharmaceutical Market by Segment (2010):Percentage Breakdown of Sales for Patent-Protected Drugs, OTCDrugs and Generic Drugs 123Spanish Government Votes for Generic Drugs 124Pharmaceutical Expenditure Continues to Plummet 124Reference Pricing in Spain Meets Tremendous Success 124

4f. SWITZERLAND 125

Swiss Pharmaceutical Market to Post Steady Growth 125

Generics Lie Low in Swiss Pharma Industry 125

Swiss Pharma Industry - A Major Global Exporter of

Pharmaceuticals 125

Appreciation of Swiss Franc Raises Concerns 125

4g. RUSSIA 127New Insurance Scheme to Drive Market 127New Laws Expand Government's Role in Pricing 127Competition Remains High 127Generic Drugs to Gain Rapid Uptake in Russia 127Domestic Industry Emphasizes on Generic Drugs 128

4h. DENMARK 129

Pharmaceutical Spending Rises 129

4i. FINLAND 129Aging Population Drives Finnish Pharmaceutical Market 129

4j. THE NETHERLANDS 130

Pricing Pressures Haunt Dutch Pharmaceuticals Market 130

4k. LITHUANIA 130Imports - A Major Source of Pharmaceuticals in Lithuania 130Private Share in Pharma Expenditure Soars 130

4l. NORWAY 131

Generics Begin to Gain Momentum 131

4m. KAZAKHSTAN 131Kazakhstan's Pharma Market to Post Robust Growth 131

4n. SERBIA 132

Serbian Pharmaceuticals Market Challenged by Several Factors 132

4o. PORTUGAL 132Uncertain Economic Conditions Mar Pharmaceuticals Sector inPortugal 132

4p. POLAND 132

Polish Pharmaceutical Market to Witness Substantial Growth 132

4q. HUNGARY 133Hungary's Pharmaceutical Sector on the Rise 133

4r. GREECE 133

Payment Woes Compel Drug Companies to Demand Cash-on-Delivery 133

5. ASIA-PACIFIC 134Asia-Pacific - The Fastest Growing Regional Market forPharmaceuticals Worldwide 134Table 36: Asia-Pacific Recent Past, Current & Future Analysisfor Prescription Pharmaceuticals by Geographic Region -China, India and Rest of Asia-Pacific Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Billion for Years2010 through 2015 135

Table 37: Asia-Pacific 5-Year Perspective for Prescription

Cards by Geographic Region - Percentage Breakdown of Dollar

Sales for China, India and Rest of Asia- Pacific Markets for

Years 2011 and 2015 136

Access to Pharmaceuticals - A Major Impediment to Asian Pharma

Market Growth 136

Lipitor - The Leading Brand in the Asia-Pacific Pharmaceutical

Market 136

Table 38: Leading Pharmaceutical Products in Asia by Revenue:

2009 137

5a. CHINA 138Chinese Pharmaceutical Market Posts Remarkable Growth 138Economic Growth Drives Pharmaceutical Expenditure 138Chinese Pharmaceutical Industry Makes a Mark for Itself 138Industry Outlook Remains Robust 139Government Increases Industry Scrutiny 139Chinese Pharmaceutical Industry Surges amid Recession 139A Strong, Innovative Pharmaceutical Industry in the Making 139Increasing Opportunities for Multinational Companies in China 140Chinese Company Makes Foray into the US 140Chinese CRO Market Grows at a Robust Pace 141Government Investments Imperative to Realize Strong IndustryGrowth 141Big MNCs Eye Chinese Pharmaceutical Industry 141Major Challenges 142Government's Pricing Reforms Puts Multinational PharmaCompanies in a Quandary 142China Faces New Challenges and Short- Term Risks 143Stringent Government Regulations Affects China'sPharmaceutical Industry 143Essential Drugs and Primary Healthcare Holds DiscouragingProspects for Multinational Pharma Companies 143

5b. AUSTRALIA 144

Tough Economic Environment Hits Pharmaceutical Market 144

Market Drivers Remain Intact 144

Changes to PBS set to Result in Dramatic Changes in the Market 144

Table 39: Leading Pharmaceutical Products in Australia by

Revenue: 2009 145

5c. INDIA 146Indian Pharma Market to Surge 146Generics Lead the Market 146Biopharmaceutical Segment Registers Strong Growth 146Diabetes and Cancer Segments-To Lead Growth 146Rapid Growth Ahead in the Indian Pharmaceutical Industry 146Indian Generic Drug Producers to See High Demand from the US 147India API Producers Eye Japanese Market 147Government Offers Ample Support for Foreign Investment 147Overseas Pharma Companies Follow Indian Counterparts to GainMarket Share 148Collaborations and Consolidation - A Major Strategy for IndiaPharma Giants 148Mergers and Acquisitions Dominate the Market Scenario 148Major Acquisitions of Indian Pharmaceutical Companies/Businesses in Recent Years 149Cipla Tops Indian Pharmaceutical Market by Value 149Table 40: Leading Indian Pharmaceutical Companies by DomesticSales: 2010 150Cough Medication Tops Indian Pharmaceutical Sales Chart 150Table 41: Leading Pharmaceutical Products in India byRevenue: 2009 150India Leads in DMF Filings in the US 151Table 42: Leading DMF Filing Countries with the US FDA: 2009 151

5d. SOUTH KOREA 152

Exports of Pharmaceutical Products Surge, Imports Remain Far

Ahead 152

Government Sees Pharma as the Next Growth Engine (Korea) 152

Government Support, Key for Growth of Innovation 152

Clinical Trials Flourish in Korea 153

Table 43: South Korean Clinical Trial Market by Number of IND

Applications Approved by Korean Food and Drug Administration 153

Plavix Stands Ahead of Lipitor in Korea 153

Table 44: Leading Pharmaceutical Products in Korea by

Revenue: 2009 154

5e. THE PHILIPPINES 155Pharmaceutical Market in the Philippines to Surge 155Consolidation within the Pharmaceutical Sector on the Cards 155

5f. THAILAND 156

Generics - A Dominant Segment in the Thai Pharmaceutical Market 156

Thailand - A Growing Domestic Market for Pharmaceuticals 156

5g. MALAYSIA 157Low Per-Capita Consumption Typifies Malaysian PharmaceuticalMarket 157Market Bodes Tremendous Growth Prospects 157Generics Dominate the Domestic Pharmaceutical Sector 157A Peek into the Malaysian Pharmaceutical Industry 158Major Drugs 159Table 45: Leading Pharmaceutical Products in Malaysia byRevenue: 2009 159

5h. PAKISTAN 160

Relatively Stable Environment to Surge Demand for Pharma Products 160

Pakistan - Still Not A Favorite Destination for Global Pharma 160

Exports Continue to Rise, Trade Balance Remains Negative 160

Lack of Price Revision - A Major Cause of Concern for Domestic

Industry 160

High Government's Share in Healthcare Spending Curbs Drug

Price Growth 161

Changing Government's View on Reimbursements to Offer Respite

to Market Growth 161

5i. VIETNAM 162Growth Abounds in the Vietnamese Pharmaceutical Market 162Increasing Drug Prices Leave Bitter Taste Among Patients 162Vietnamese Pharmaceutical Market Fares Well During Recession 163Industry Depends Immensely on Imports 163Commitment to WTO Opens Vietnamese Market for Foreign Players 163Pharmaceutical Imports Continue to Rise 164

5j. SRI LANKA 164

Sri Lankan Pharmaceutical Market - Going Strong 164

High Reliance on Imports - A Cause of Concern to the Industry 164

5k. SINGAPORE 165Singapore - More Promising for Pharmaceutical Research Segment 165Roche's Products Lead Singapore's Pharmaceutical Market 165Table 46: Leading Pharmaceutical Products in Singapore byRevenue: 2009 165

5l. INDONESIA 166

Overseas Companies Lose Ground in Indonesian Pharmaceutical

Industry 166

6. LATIN AMERICA 167Latin American Pharmaceutical Market Surges Ahead 167Generic Drug Market Picking Up in Latin America 167

6a. BRAZIL 168

Foreign Manufacturers Storm into Brazilian Pharmaceutical Sector 168

6b. ARGENTINA 169Argentinean Pharmaceutical Market to Post Robust Growth 169A Strong Domestic Industry Supports Argentinean PharmaceuticalMarket 169

6c. VENEZUELA 169

Market Overview 169

6d. MEXICO 170Host of Factors to Restrain Future Growth in Market 170

6e. CHILE 170

Chilean Pharmaceutical Sector - A Snapshot 170

6f. COLOMBIA 171Market Overview & Outlook 171

6g. PERU 171

Market Overview 171

6h. CUBA 172Cuban Pharmaceutical Market - The Smallest in the Region 172

7. REST OF WORLD 173

Middle East and Africa Augurs Huge Growth Prospects for Global

Pharmaceutical Industry 173

Diverse Healthcare Systems in the MEA Region 173

Multinational Companies Flock MEA Region 173

Overview of Middle East Pharmaceutical Market 174

7a. SAUDI ARABIA 175Saudi Arabia - A Lucrative Market in the Region 175Generic Drugs - A Major Focus of the Domestic Industry 175Presence of Overseas Players Increases in the SaudiPharmaceutical Industry 175Pharmaceutical Exports on the Rise 176Industry Battles Issues 176

7b. UNITED ARAB EMIRATES 177

A Glimpse of UAE Pharmaceutical Industry 177

Investments Remain a Lackluster Affair 177

Major Players 177

Recent Events Tighten Manufacturers' Profitability 178

7c. EGYPT 178Overview 178

7d. JORDAN 179

Overview 179

7e. MOROCCO 179Overview 179

7f. TURKEY 180

Overview 180

7g. OMAN 180Overview 180GLOBAL DIRECTORY